While immune-based lineage depletion is clinically effective in B lineage malignancies based on restricted expression of CD19 and CD20, effective AML depletion therapies remain elusive because immature AML blasts share surface antigens with normal myeloid progenitors essential for survival54. This evidence concerns the gene CD19 and acute myeloid leukemia.